Jury orders Abbott to pay $53 million in preterm infant formula trial, media report says

A Texas jury has ordered global healthcare company Abbott Laboratories to pay $53 million in damages to a family in St. Louis, Missouri, following a verdict delivered on Wednesday, May 15, 2024. The lawsuit alleged that Abbott's Similac Special Care formula, designed for premature infants, caused a severe and life-threatening intestinal disease known as necrotizing enterocolitis (NEC) in a premature baby, leading to significant medical complications and lifelong health issues. This case is one of the first to reach a verdict among hundreds of similar lawsuits consolidated in federal court, setting a significant legal and financial precedent for the massive litigation facing the infant formula manufacturer. The trial centered on the specific claims of the family, whose child was born prematurely and fed Similac Special Care in a neonatal intensive care unit (NICU). Their legal team successfully argued that Abbott failed to adequately warn parents and medical professionals about the heightened risks of NEC associated with its cow's milk-based formula for preterm infants, compared to human breast milk. NEC is a devastating condition where intestinal tissue becomes inflamed and dies, and it carries a high mortality rate, particularly for vulnerable preemies. The jury's award includes compensation for the child's past and future medical care, pain and suffering, and other damages, reflecting the severity of the alleged harm. This verdict sends a powerful signal through the broader multidistrict litigation (MDL), where over 400 similar lawsuits are pending against Abbott and another major formula maker, Mead Johnson. The litigation claims that these companies prioritized profits over safety by marketing their products for use with premature infants without sufficient warnings. While Abbott has stated it will appeal the verdict and stands by the safety of its products, this multi-million dollar judgment may influence settlement negotiations and the legal strategy for the remaining cases. The outcome also places renewed scrutiny on the standards and transparency within the multi-billion dollar infant formula industry, particularly concerning products for the most medically fragile newborns.